GlassScriptPhysician profile
Jeanette Lee
NPI 1629090048
$8,157.09
in general payments reported to CMS, 2019-2025
22 companies · $2,384 in 2025
The $2,384 reported for 2025 was more than what 97% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $591 · 2020: $205 · 2021: $818 · 2022: $1,357 · 2023: $1,704 · 2024: $1,097 · 2025: $2,384.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,034 · Consulting Fee: $701 · Gift: $450.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,033.94 |
| Consulting Fee | $700.91 |
| Gift | $450.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Johnson & Johnson Vision Care, INC. | $3,622.38 | 2019-2025 | Acuvue |
| Tarsus Pharmaceuticals, INC. | $959.42 | 2024-2025 | Xdemvy |
| Visionary Optics LLC | $750.00 | 2019-2023 | |
| Lumenis Be INC | $697.83 | 2023-2024 | M22, Optilight |
| Alcon Vision LLC | $284.29 | 2025 | Tryptyr |
| Glaukos Corporation | $280.57 | 2021-2025 | Photrexa Viscous and Photrexa, Kxl System (Not Refurbished) |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $257.53 | 2021 | |
| Oyster Point Pharma, INC. | $254.57 | 2022-2024 | Tyrvaya |
| Johnson & Johnson Surgical Vision, INC. | $243.79 | 2021-2025 | Lipiflow System Activator (Disposable), Meibomian Gland Evaluator |
| Horizon Therapeutics Plc | $173.16 | 2023 | Tepezza |
| Sun Pharmaceutical Industries INC. | $122.36 | 2023 | Cequa |
| Coopervision INC. | $117.21 | 2022 | |
| Optovue, INC. | $71.40 | 2019 | |
| Kala Pharmaceuticals, INC. | $56.20 | 2021-2022 | |
| Amgen INC. | $49.55 | 2024-2025 | Tepezza |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biotissue Holdings INC. | $39.68 | 2021-2024 | |
| Abb Con-Cise Optical Group LLC | $36.21 | 2019 | |
| Sight Sciences, INC. | $35.38 | 2022 | |
| Abbvie INC. | $32.45 | 2023 | |
| Bausch & Lomb Americas INC. | $27.09 | 2023 | Infuse |
| Eyevance Pharmaceuticals LLC | $23.82 | 2023 | Flarex |
| Allergan, INC. | $22.20 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeanette Lee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.